Literature DB >> 10098101

Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver.

Y N Sun1, D C DuBois, R R Almon, W J Jusko.   

Abstract

A fourth-generation pharmacokinetic/pharmacodynamic (PK/PD) model for receptor/genemediated effects of corticosteroids was developed. Male adrenalectomized Wistar rats received a 50 mg/kg i.v. bolus dose of methylprednisolone (MPL). Plasma concentrations of MPL, hepatic glucocorticoid receptor (GR) messenger RNA (mRNA) and GR density, tyrosine amino-transferase (TAT) mRNA, and TAT activity in liver were determined at various time points up to 72 hr after MPL dosing. Down-regulation of GR mRNA and GR density were observed: GR mRNA level declined to 45-50% of the baseline in 8-10 hr, and slowly returned to predose level in about 3 days; GR density fell to 0 soon after dosing and returned to the baseline in two phases. The first phase, occurring in the first 10 hr, entailed recovery from 0 to 30%. The second phase was parallel to the GR mRNA recovery phase. Two indirect response models were applied for GR mRNA dynamics regulated by activated steroid-receptor complex. A full PK/PD model for GR mRNA/GR down-regulation was proposed, including GR recycling theory. TAT mRNA began to increase at about 1.5 hr, reached the maximum at about 5.5 hr, and declined to the baseline at about 14 hr after MPL dosing. TAT induction followed a similar pattern with a delay of about 1-2 hr. A transcription compartment was applied as one of the cascade events leading to TAT mRNA and TAT induction. Pharmacodynamic parameters were obtained by fitting seven differential equations piecewise using the maximum likelihood method in the ADAPT II program. This model can describe GR down-regulation and the precursor/product relationship between TAT mRNA and TAT in receptor/gene-mediated corticosteroid effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10098101     DOI: 10.1023/a:1023233409550

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  51 in total

1.  Glucocorticosteroid receptor dimerization investigated by analysis of receptor binding to glucocorticosteroid responsive elements using a monomer-dimer equilibrium model.

Authors:  I Segard-Maurel; K Rajkowski; N Jibard; G Schweizer-Groyer; E E Baulieu; F Cadepond
Journal:  Biochemistry       Date:  1996-02-06       Impact factor: 3.162

2.  Prednisone side-effects and serum-protein levels. A collaborative study.

Authors:  G P Lewis; W J Jusko; L Graves; C W Burke
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

Review 3.  Homologous down regulation of the glucocorticoid receptor: the molecular machinery.

Authors:  R H Oakley; J A Cidlowski
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1993       Impact factor: 1.807

4.  Characterization of the protein-protein interactions determining the heat shock protein (hsp90.hsp70.hsp56) heterocomplex.

Authors:  M J Czar; J K Owens-Grillo; K D Dittmar; K A Hutchison; A M Zacharek; K L Leach; M R Deibel; W B Pratt
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

5.  Dose dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J Q Rose; A M Yurchak; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

6.  Regulation of glucocorticoid receptor protein and mRNA levels.

Authors:  W V Vedeckis; M Ali; H R Allen
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

7.  Dynamics of glucocorticoid receptor and induction of tyrosine aminotransferase in rat liver.

Authors:  M Izawa; A Yoshida; S Ichii
Journal:  Endocrinol Jpn       Date:  1982-04

8.  Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes.

Authors:  L E Fisher; E A Ludwig; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1992-08

9.  Receptor-mediated methylprednisolone pharmacodynamics in rats: steroid-induced receptor down-regulation.

Authors:  D B Haughey; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1992-08

10.  Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids.

Authors:  R I Scheinman; P C Cogswell; A K Lofquist; A S Baldwin
Journal:  Science       Date:  1995-10-13       Impact factor: 47.728

View more
  38 in total

1.  Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.

Authors:  R Gieschke; J L Steimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

2.  The genomic response of skeletal muscle to methylprednisolone using microarrays: tailoring data mining to the structure of the pharmacogenomic time series.

Authors:  Richard R Almon; Debra C DuBois; William H Piel; William J Jusko
Journal:  Pharmacogenomics       Date:  2004-07       Impact factor: 2.533

3.  Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats.

Authors:  Anasuya Hazra; Nancy A Pyszczynski; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

4.  Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series.

Authors:  Richard R Almon; Debra C Dubois; Jin Y Jin; William J Jusko
Journal:  AAPS J       Date:  2005-08-18       Impact factor: 4.009

5.  A stochastic version of corticosteriod pharmacogenomic model.

Authors:  Xiaohong Qi
Journal:  AAPS J       Date:  2005-06-23       Impact factor: 4.009

6.  Corticosteroid-regulated genes in rat kidney: mining time series array data.

Authors:  Richard R Almon; William Lai; Debra C DuBois; William J Jusko
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-06-28       Impact factor: 4.310

7.  Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle.

Authors:  Richard R Almon; Debra C Dubois; Jin Y Jin; William J Jusko
Journal:  J Endocrinol       Date:  2005-01       Impact factor: 4.286

8.  Application of scaling factors in simultaneous modeling of microarray data from diverse chips.

Authors:  Zhenling Yao; Baiteng Zhao; Eric P Hoffman; Svetlana Ghimbovschi; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Pharm Res       Date:  2007-02-21       Impact factor: 4.200

Review 9.  Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development.

Authors:  Robert M Straubinger; Wojciech Krzyzanski; Crystal M Francoforte; Jun Qu
Journal:  Anticancer Res       Date:  2007 May-Jun       Impact factor: 2.480

10.  Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens.

Authors:  Richard R Almon; Debra C DuBois; Zhenling Yao; Eric P Hoffman; Svetlana Ghimbovschi; William J Jusko
Journal:  Physiol Genomics       Date:  2007-05-01       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.